693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market https://www.fool.com/investing/2017/10/29/a-me-too-push-by-biopharma-is-crowding-the-psorisi.aspx?source=iedfolrf0000001 Oct 29, 2017 - The market for psoriasis drugs has never been more competitive, and that's boosting risk for investors.
A Slew Of Q3 Earnings http://www.zacks.com/stock/news/279939/a-slew-of-q3-earnings?cid=CS-ZC--279939 Oct 24, 2017 - A Slew Of Q3 Earnings
Big Morning of Q3 Earnings Beats http://www.zacks.com/stock/news/279922/big-morning-of-q3-earnings-beats?cid=CS-ZC-FT-279922 Oct 24, 2017 - Most major companies reporting before the opening bell today have outperformed expectations -- in some cases by a wide margin.
10 Stunning Numbers You Need to Know About Breast Cancer https://www.fool.com/investing/2017/10/18/10-stunning-number-you-need-to-know-about-breast-c.aspx?source=iedfolrf0000001 Oct 18, 2017 - There's more good news than you might think.
3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report https://www.fool.com/investing/2017/10/17/3-things-you-wont-learn-by-focusing-on-johnson-joh.aspx?source=iedfolrf0000001 Oct 17, 2017 - Despite a strong earnings beat, not everything went J&J's way in the third quarter.
Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute http://www.zacks.com/stock/news/277959/lilly-wins-favorable-ruling-from-us-pto-in-alimta-dispute?cid=CS-ZC-FT-277959 Oct 06, 2017 - Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
These Are the Top 5 Stocks the Smart Money Is Selling https://www.fool.com/investing/2017/10/02/these-are-the-top-5-stocks-the-smart-money-is-sell.aspx?source=iedfolrf0000001 Oct 02, 2017 - When the smart money exits a position, it should give you a noodle point about why they're selling.
1 Great Biotech Stock You Have Never Heard Of https://www.fool.com/investing/2017/09/29/1-great-biotech-stock-you-have-never-heard-of.aspx?source=iedfolrf0000001 Sep 29, 2017 - Big pharma companies have thrown hundreds of millions of dollars at this small biotech. Should retail investors follow suit?
Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why http://www.zacks.com/stock/news/277023/axovant-sciences-axon-stock-crashed-over-70-heres-why?cid=CS-ZC-FT-277023 Sep 26, 2017 - On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.
AstraZeneca Stock Upgraded: What You Need to Know https://www.fool.com/investing/2017/09/22/astrazeneca-stock-upgraded-what-you-need-to-know.aspx?source=iedfolrf0000001 Sep 22, 2017 - Bernstein sees opportunity in a buyout target.

Pages: 1...5051525354555657585960...70

<<<Page 55>